ADARx Pharmaceuticals stock analysis
ADARx Pharmaceuticals (ADRX) Stock Price & Analysis
ADRX Stock Chart & Stats
- Day’s Range
- $12.90 - $14.96
- 52-Week Range
- $12.50 - $23.21
- Previous Close
- $14.00
- Volume
- N/A
- Average Volume (3M)
- 446.70K
- Market Cap
- $1.54B
- Enterprise Value
- $1.24B
- Total Cash (Recent Filing)
- $901.01M
- Total Debt (Recent Filing)
- $6.46M
- Price to Earnings (P/E)
- ―
- Beta
- 3.84
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
ADRX FAQ
What was ADARx Pharmaceuticals’s price range in the past 12 months?
What is ADARx Pharmaceuticals’s market cap?
When is ADARx Pharmaceuticals’s upcoming earnings report date?
How were ADARx Pharmaceuticals’s earnings last quarter?
Is ADARx Pharmaceuticals overvalued?
Does ADARx Pharmaceuticals pay dividends?
What is ADARx Pharmaceuticals’s EPS estimate?
How many shares outstanding does ADARx Pharmaceuticals have?
What happened to ADARx Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ADARx Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
ADARx Pharmaceuticals Stock Smart Score
Company Description
ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhen Li
- Employees
- 100
- Website
- www.adarx.com
- Address
- 5871 Oberlin Drive, Suite 200, San Diego, CA, 92121, US
ADARx Pharmaceuticals (ADRX) Earnings & Revenues
ADRX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 6 |










